PBD Biotech specialises in novel phage-based diagnostics for the veterinary, agriculture and human health sectors
PBD Biotech has developed the only rapid, sensitive test to detect live mycobacteria, which are responsible for bovine TB and Johne’s Disease, both economically disastrous. Trials have demonstrated the effectiveness of Actiphage, which can detect mycobacteria at low levels in blood or milk within six hours. The test has applications in quality control of dairy products, and could revolutionise the way bovine TB and other livestock diseases are identified and managed. Since the company established, it has gained funding, UK government approval for exceptional private use, proven efficacy in the field, opened an office in Canada and trials are currently underway on farms, in hospital and with national institutions around the world.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 30, 2021 | Series Unknown | $2.30M | 2 | Mercia Fund Managers Foresight Group | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Mercia Fund Managers | Yes | Series Unknown |
Foresight Group | Yes | Series Unknown |